Pharmacovigilance

March 22, 2019 9:03 am Published by medication

13:45-14:15: The importance of Robust PV systems
14:15-14:45: Post Marketing Surveillance of Biosimilars
14:45-15:15: Risk Management Plans- Originator and Biosimilars
15:15-15:45: Case Study: Epo and PRCA
15:45-16:30: Panel Discussion with all participants and afternoon tea

Categorised in:

This post was written by medication